High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer

Anticancer Research

Volumn 29, Issue 3, 2009, Pages 809-816

  Ohno, Satoshi ^a,b   Ohno, Yumiko ^b   Suzuki, Nobutaka ^a,b   Soma, Gen Ichiro ^c,d,e   Inoue, Masaki ^b  

^a Department of Complementary   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^d TOKYO UNIVERSITY OF SCIENCE   (Japan)

^e KAGAWA UNIVERSITY   (Japan)

Author keywords

Ascorbate; Ascorbic acid; Cancer; Complementary and alternative medicine; Cytotoxicity; Intravenous; Plasma concentration; Review; Vitamin C

Indexed keywords

ASCORBIC ACID; DOXORUBICIN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER PATIENT; CANCER THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG ADMINISTRATION ROUTE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HEMOLYSIS; HUMAN; INTESTINE DISTENSION; IRON ABSORPTION; MONOTHERAPY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; URINARY EXCRETION;

ANTIOXIDANTS; ASCORBIC ACID; HUMANS; NEOPLASMS;

EID: 64949179184     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (56)

1. Block G: Epidemiologic evidence regarding vitamin C and cancer. Am J Clin Nutr 54: 1310S-1314S, 1991.
2. Cameron E and Pauling L: Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 73: 3685-3689, 1976.
3. Cameron E and Pauling L: Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 75: 4538-4542, 1978.
4. Murata A, Morishige F and Yamaguchi H: Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. Int J Vitam Nutr Res Suppl 23: 103- 113, 1982.
5. Campbell A, Jack T and Cameron E: Reticulum cell sarcoma: two complete 'spontaneous' regressions, in response to high- dose ascorbic acid therapy. A report on subsequent progress. Oncology 48: 495-497, 1991.
6. Creagan ET, Moertel CG, O'Fallon JR, Schutt AJ, O'Connell MJ, Rubin J and Frytak S: Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 301: 687-690, 1979.
7. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ and Ames MM: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 312: 137-141, 1985.
8. Riordan HD, Hunninghake RB, Riordan NH, Jackson JJ, Meng X, Taylor P, Casciari JJ, Gonzalez MJ, Miranda-Massari JR, Mora EM, Rosario N and Rivera A: Intravenous ascorbic acid: protocol for its application and use. P R Health Sci J 22: 287-290, 2003.
9. Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, Wesley RA and Levine M: Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140: 533-537, 2004.
10. Padayatty SJ and Levine M: Reevaluation of ascorbate in cancer treatment: emerging evidence, open minds and serendipity. J Am Coll Nutr 19: 423-425, 2000.
11. McCormick WJ: Cancer: the preconditioning factor in pathogenesis; a new etiologic approach. Arch Pediatr 71: 313- 322, 1954.
12. McCormick WJ: Cancer: a collagen disease, secondary to a nutritional deficiency. Arch Pediatr 76: 166-171, 1959.
13. Cameron E and Rotman D: Ascorbic acid, cell proliferation, and cancer. Lancet 1: 542, 1972.
14. Cameron E and Pauling L: Ascorbic acid and the glycosaminoglycans. An orthomolecular approach to cancer and other diseases. Oncology 27: 181-192, 1973.
15. Cameron E and Campbell A: The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact 9: 285-315, 1974.
16. Cameron E and Campbell A: Innovation vs. quality control: an 'unpublishable' clinical trial of supplemental ascorbate in incurable cancer. Med Hypotheses 36: 185-189, 1991.
17. Graumlich JF, Ludden TM, Conry-Cantilena C, Cantilena LR Jr, Wang Y and Levine M: Pharmacokinetic model of ascorbic acid in healthy male volunteers during depletion and repletion. Pharm Res 14: 1133-1139, 1997.
18. Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR, Park JB, Lazarev A, Graumlich JF, King J and Cantilena LR: Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 93: 3704-3709, 1996.
19. Riordan NH, Riordan HD, Meng X, Li Y and Jackson JA: Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Med Hypotheses 44: 207-213, 1995.
20. Honegger CG, Torhorst J, Langemann H, Kabiersch A and Krenger W: Quantitative determination of water-soluble scavengers in neoplastic and non- neoplastic human breast tissue. Int J Cancer 41: 690-694, 1988.
21. Langemann H, Torhorst J, Kabiersch A, Krenger W and Honegger CG: Quantitative determination of water- and lipid- soluble antioxidants in neoplastic and non-neoplastic human breast tissue. Int J Cancer 43: 1169-1173, 1989.
22. Agus DB, Vera JC and Golde DW: Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res 59: 4555-4558, 1999.
23. Levine M, Rumsey SC, Daruwala R, Park JB and Wang Y: Criteria and recommendations for vitamin C intake. JAMA 281: 1415-1423, 1999.
24. Cameron E, Pauling L and Leibovitz B: Ascorbic acid and cancer: a review. Cancer Res 39: 663-681, 1979.
25. Benade L, Howard T and Burk D: Synergistic killing of Ehrlich ascites carcinoma cells by ascorbate and 3-amino-l,2,4,-triazole. Oncology 23: 33-43, 1969.
26. Bram S, Froussard P, Guichard M, Jasmin C, Augery Y, Sinoussi- Barre F and Wray W: Vitamin C preferential toxicity for malignant melanoma cells. Nature 284: 629-631, 1980.
27. Leung PY, Miyashita K, Young M and Tsao CS: Cytotoxic effect of ascorbate and its derivatives on cultured malignant and nonmalignant cell lines. Anticancer Res 13: 475-480, 1993.
28. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E and Levine M: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a prodrug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 102: 13604-13609, 2005.
29. Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E, Choyke PL, Pooput C, Kirk KL, Buettner GR and Levine M: Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA 104: 8749-8754, 2007.
30. Amacher DE and Paillet SC: Ascorbate is detectably mutagenic in the L5178Y TK+/- cell mutation assay. Cancer Lett 14: 151- 158, 1981.
31. Miwa N, Yamazaki H and Ikari Y: Enhancement of ascorbate cytotoxicity by chelation with ferrous ions through prolonged duration of the action. Anticancer Res 6: 1033-1036, 1986.
32. 2 gradients across biomembranes. FEBS Lett 475: 121-126, 2000.
33. Schraufstatter IU, Hinshaw DB, Hyslop PA, Spragg RG and Cochrane CG: Glutathione cycle activity and pyridine nucleotide levels in oxidant- induced injury of cells. J Clin Invest 76: 1131- 1139,1985.
34. Schraufstatter IU, Hinshaw DB, Hyslop PA, Spragg RG and Cochrane CG: Oxidant injury of cells. DNA strand-breaks activate polyadenosine diphosphate- ribose polymerase and lead to depletion of nicotinamide adenine dinucleotide. J Clin Invest 77: 1312-1320, 1986.
35. Hyslop PA, Hinshaw DB, Halsey WA Jr, Schraufstatter IU, Sauerheber RD, Spragg RG, Jackson JH and Cochrane CG: Mechanisms of oxidant- mediated cell injury. The glycolytic and mitochondrial pathways of ADP phosphorylation are major intracellular targets inactivated by hydrogen peroxide. J Biol Chem 263: 1665-1675, 1988.
36. Hampton MB and Orrenius S: Dual regulation of caspase activity by hydrogen peroxide: implications for apoptosis. FEBS Lett 414: 552-556, 1997.
37. Lee YJ and Shacter E: Oxidative stress inhibits apoptosis in human lymphoma cells. J Biol Chem 274: 19792-19798, 1999.
38. Comelli M, Di Pancrazio F and Mavelli I: Apoptosis is induced by decline of mitochondrial ATP synthesis in erythroleukemia cells. Free Radic Biol Med 34: 1190-1199, 2003.
39. 2 mediate glucose deprivation-induced stress in human cancer cells. J Biol Chem 280: 4254-4263, 2005.
40. Shimpo K, Nagatsu T, Yamada K, Sato T, Niimi H, Shamoto M, Takeuchi T, Umezawa H and Fujita K: Ascorbic acid and adriamycin toxicity. Am J Clin Nutr 54: 1298S-1301S, 1991.
41. Prasad KN, Hernandez C, Edwards- Prasad J, Nelson J, Bonis T and Robinson WA: Modification of the effect of tamoxifen, cis- platin, DTIC, and interferon- alpha 2b on human melanoma cells in culture by a mixture of vitamins. Nutr Cancer 22: 233-245, 1994.
42. Kurbacher CM, Wagner U, Kolster B, Andreotti PE, Krebs D and Bruckner HW: Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett 103: 183- 189, 1996.
43. Taper HS, de Gerlache J, Lans M and Roberfroid M: Non-toxic potentiation of cancer chemotherapy by combined C and K3 vitamin pre- treatment. Int J Cancer 40: 575-579, 1987.
44. Fain O, Mathieu E and Thomas M: Scurvy in patients with cancer. BMJ 316: 1661-1662, 1998.
45. Chandra RK: Impact of nutritional status and nutrient supplements on immune responses and incidence of infection in older individuals. Ageing Res Rev 3: 91-104, 2004.
46. Bendich A: Vitamin C and immune responses. Food Technol 41: 112-114,1987.
47. Scott JA: On the biochemical similarities of ascorbic acid and interferon. J Theor Biol 98: 235-238, 1982.
48. Murray MT and Bongiorno PB: Vitamin Toxicities and Therapeutic Monitoring. Pizzorno JE and Murray MT (eds.). St. Louis, Churchill Livingstone Elsevier, pp. 1389-1393, 2006.
49. Casciari JJ, Riordan HD, Miranda-Massari JR and Gonzalez MJ: Effects of high-dose ascorbate administration on L-10 tumor growth in guinea pigs. P R Health Sci J 24: 145-150, 2005.
50. Wong K, Thomson C, Bailey RR, McDiarmid S and Gardner J: Acute oxalate nephropathy after a massive intravenous dose of vitamin C. Aust N Z J Med 24: 410-411, 1994.
51. Campbell A and Jack T: Acute reactions to mega ascorbic acid therapy in malignant disease. Scott Med J 24: 151-153, 1979.
52. Rivers JM: Safety of high-level vitamin C ingestion. Ann NY Acad Sci 498: 445-454, 1987.
53. Block KI, Koch AC, Mead MN, Tothy PK, Newman RA and Gyllenhaal C: Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials. Cancer Treat Rev 33: 407- 418, 2007.
54. White JD: Complementary and alternative medicine research: a National Cancer Institute perspective. Semin Oncol 29: 546-551, 2002.
55. Nahin RL: Use of the best case series to evaluate complementary and alternative therapies for cancer: a systematic review. Semin Oncol 29: 552-562, 2002.
56. Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ and Levine M: Intravenously administered vitamin C as cancer therapy: three cases. Can Med Assoc J 174: 937-942, 2006.